2% Lidocaine Plus 0.5% Bupivacaine Versus 0.5% Bupivacaine in Brachial Block for Creation of Arteriovenous (AV) Fistula

The recruitment status of this study is unknown because the information has not been verified recently.
Verified October 2009 by Mahidol University.
Recruitment status was  Recruiting
Sponsor:
Information provided by:
Mahidol University
ClinicalTrials.gov Identifier:
NCT00993746
First received: September 27, 2009
Last updated: May 14, 2010
Last verified: October 2009

September 27, 2009
May 14, 2010
October 2009
September 2010   (final data collection date for primary outcome measure)
onset of sensory block [ Time Frame: 24 hour ] [ Designated as safety issue: Yes ]
Same as current
Complete list of historical versions of study NCT00993746 on ClinicalTrials.gov Archive Site
onset of motor block [ Time Frame: 24 hour ] [ Designated as safety issue: Yes ]
Same as current
Not Provided
Not Provided
 
2% Lidocaine Plus 0.5% Bupivacaine Versus 0.5% Bupivacaine in Brachial Block for Creation of Arteriovenous (AV) Fistula
Comparison of Onset of Action Between 2% Lidocaine Plus 0.5% Bupivacaine and 0.5% Bupivacaine in Brachial Plexus Anesthesia for Creation of Arteriovenous Fistula in ESRD Patient

Will the technique of adding lidocaine to bupivacaine fasten the onset of bupivacaine alone for infraclavicular brachial plexus block in end-stage renal disease (ESRD) patient?

Not Provided
Interventional
Phase 4
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Infraclavicular Brachial Plexus Block
  • Drug: Bupivacaine plus lidocaine
    Bupivacaine 20 ml plus lidocaine 10 ml
    Other Name: Marcaine Xylocaine
  • Drug: Bupivacaine 30 ml
    Bupivacaine 30 ml for ultrasound guided infraclavicular brachial plexus block
    Other Name: lidocaine, marcaine
  • Active Comparator: Bupivacaine plus lidocaine
    Group 1: bupivacaine 20 ml plus lidocaine 10 ml
    Intervention: Drug: Bupivacaine plus lidocaine
  • Experimental: Bupivacaine alone
    Group 2: bupivacaine 30 ml
    Intervention: Drug: Bupivacaine 30 ml
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
90
September 2011
September 2010   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • ESRD patient for AVF procedure
  • age >17 year
  • BMI 20-35 kg/m2
  • communicable

Exclusion Criteria:

  • BMI > 35 kg/m2 BMI < 20 kg/m2 หรือ BW < 35 kg
  • History of allergy to local anesthetic drugs
  • Pre-operative neurological deficit, Neuromuscular disorder หรือ old CVA
  • Psychiatric disorder
  • Coagulation disorder
  • Uncontrolled seizure
  • Pregnant and lactating women
Both
18 Years and older
No
Contact: Orawan Pongraweewan, MD,FRCA 6681-4317599 pongraweewan@yahoo.com
Thailand
 
NCT00993746
si433/2009
No
Faculty of Medicine Siriraj Hospital, Mahidol University
Mahidol University
Not Provided
Principal Investigator: Orawan Pongrawewan, MD Siriraj Hospital
Mahidol University
October 2009

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP